CoChat

High-Dose Olanzapine for Treatment-Refractory Schizophrenia

Lerner, Vladimir · 2003 · Clinical Neuropharmacology

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Abstract

To date there is no common or adequate therapeutic strategy for treatment of refractory schizophrenic patients. Increasing antipsychotics' doses in treatment-resistant schizophrenic patients is the most common intervention used by clinicians. Olanzapine is an atypical antipsychotic, which in a number of double-blind, placebo-controlled studies has been found to be more effective than haloperidol for the treatment of positive and negative symptoms of schizophrenia. During the last few years there have been several reports of successful results in prescribing olanzapine at dosages of more than 25 mg/day for treatment-resistant schizophrenic and schizoaffective patients. This report presents the results from the treatment of three resistant schizophrenic patients treated successfully with high dosages of olanzapine (35, 40, and 60 mg/day). None of the patients had any side effects, including abnormal laboratory levels and weight gain. The results and literature data suggest that in clinical practice some schizophrenic patients resistant to conventional neuroleptic treatment and not responding to olanzapine at recommended dosages as high as 20 mg/day may respond to higher dosages such as 40 or 60 mg/day, and these dosages are well tolerated. Further prospective clinical studies are needed.

Overview

Integrity signals

Registry

Crossref · 10.1097/00002826-200303000-00003

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Research works printed but not linked: 5

  1. Daniel, 1998, J Clin Psychiatry, 59, 13
  2. Marder, 1996, J Clin Psychiatry, 57, 26
  3. Beasley, 1997, J Clin Psychiatry, 58, 13
  4. Kane, 1999, J Clin Psychiatry, 60, 13
  5. Peuskens, 1999, J Clin Psychiatry, 60, 4

Cited by

See all 29

Metadata

Authors
Lerner, V.
Affiliations
Ben-Gurion University of the Negev (IL)
Corresponding author
Lerner, Vladimir
Venue
Clinical Neuropharmacology
Published
2003-03
Volume
26
Issue
2
Pages
58-61
ISSN
0362-5664 (ISSN-L)
OpenAlex
W1973272294
Cited by
29
References
29
Citations by year
2022: 1 · 2021: 1 · 2020: 1 · 2018: 4 · 2015: 2 · 2014: 1 · 2013: 1
FWCI
2.04
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
olanzapine, high-dose antipsychotics, treatment-resistant schizophrenia, atypical antipsychotics, dose escalation, schizoaffective disorder, adverse effects, weight gain
MeSH terms
Olanzapine, Adult, Benzodiazepines, Female, Humans, Male, Pirenzepine, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-Dose Olanzapine for Treatment-Refractory Schizophrenia. https://app.cochat.ai/papers/10.1097/00002826-200303000-00003
The paper
Lerner, V. (2003). High-Dose Olanzapine for Treatment-Refractory Schizophrenia. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-200303000-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.